Davita Inc vs Rivian Automotive, Inc. — how do they compare? Davita Inc trades at $178.83 (market cap $11.38B), while Rivian Automotive, Inc. trades at $16.23 (market cap $23.69B). The key difference: Rivian Automotive, Inc. is far larger — about 2.1× Davita Inc's market cap, and Davita Inc is trading nearer its 52-week high, Rivian Automotive, Inc. nearer its low. Which is the better fit depends on your goals.
| DVA | RIVN | |
|---|---|---|
Market Cap | $11.38B | $23.69B |
Sector | Health | Consumer Cyclical |
52-Week High | $240.96 | $22.45 |
52-Week Low | $103.87 | $11.97 |
Enterprise Value | $24.10B | $23.73B |
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $183.69, down slightly by 0.04% over the past day. The stock shows strong fundamental performance with consistent earnings beats in recent quarters, including Q2 2026 EPS of $4.02 versus $3.88 expected (Zacks Investment Research, 2026-08-04). However, technical indicators signal a bearish trend, with the price near key support at $182. Revenue growth remains steady, climbing to $13.64 billion in 2025, though net income margin dipped to 5.47%.
The outlook is mixed; analyst consensus leans bullish with a $232.25 price target (MarketBeat, 2026-08-05), but risks include reimbursement pressure and high debt levels. Investment appeal hinges on execution against guidance amid payer-mix challenges, with the current valuation offering potential upside if operational trends stabilize.
Rivian (RIVN) trades at $16.39, up 2.44% today, showing bullish technical signals with recent price momentum. The company continues to narrow losses, with Q2 2026 EPS beating expectations at -$0.47 versus -$0.66 expected. Revenue growth is steady, reaching $5.39B in 2025, while cash burn remains a key focus as the R2 vehicle ramp-up progresses.
Outlook is cautiously optimistic with analyst consensus price target of $18.70 offering potential upside. Key opportunities include R2 demand and margin improvements, but risks from high cash burn and competitive pressures persist. Execution on profitability targets will be critical for sustained stock appreciation.
Trailing returns across standard periods
Latest headlines on both assets
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →Rivian Automotive, Inc. is an automotive technology company. The Company designs and manufactures vans, trucks, and sports utility vehicles, as well as offers repair and maintenance services. Rivian Automotive serves customers in North America and the United Kingdom.
Read more on RIVN →